New combo therapy aims to shrink untreatable liver tumors
NCT ID NCT06794073
First seen May 12, 2026 · Last updated Jun 21, 2026 · Updated 4 times
Summary
This study tests a powerful combination of treatments for people with advanced liver cancer that cannot be surgically removed. The approach uses heat-based ablation to destroy the main tumor, followed by targeted therapy (lenvatinib), immunotherapy (tislelizumab), and a procedure that blocks the tumor's blood supply (TACE). The goal is to see if this multi-pronged attack can shrink tumors and improve survival. The trial is small, with only 17 participants, and is being conducted at a single center in China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (PD-1 monoclonal antibody), lenvatinib, multimodal thermal ablation, and transarterial chemoembolization (TACE)
What this could lead to
If successful, this combination could shrink or control liver tumors that cannot be removed by surgery, potentially extending survival.
What could go wrong
This is a very small, early-phase trial with only 17 people and no comparison group. The combination may cause significant side effects, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.